Hemoglobin-catalyzed transformation of elliptinium acetate into electrophilic species. Evidences for oxidative activation of the drug in human red blood cells.
The anti-tumor drug N2-methyl-9-hydroxyellipticinium acetate (NMHE, Celiptium) after incubation with various N or S containing amino acids (alanine, histidine, aspartic acid, cysteine, glutathione) with hemoglobin and hydrogen peroxide or an organic peroxide (terbutylhydroperoxide) leads to the formation of the corresponding covalent binding adducts, via an oxidative activation. The formation of the covalent adduct glutathione-elliptinium was also demonstrated in human red blood cells. The importance of such process under in vivo conditions is discussed.
Ha
T
T
Laboratoire de Pharmacologie et Toxicologie Fondamentales du CNRS, Toulouse, France.
Bernadou
J
J
Voisin
E
E
Auclair
C
C
Meunier
B
B
D000470:Alkaloids / Q000378:metabolism*; D000596:Amino Acids / Q000378:metabolism; D001711:Biotransformation; D002570:Ceruloplasmin / Q000378:metabolism; D004611:Ellipticines / Q000378:metabolism*; D004912:Erythrocytes / Q000378:metabolism*; D005978:Glutathione / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D010084:Oxidation-Reduction; D010100:Oxygen / Q000378:metabolism; D010545:Peroxides / Q000378:metabolism
D000470:Alkaloids; D000596:Amino Acids; D004611:Ellipticines; D006454:Hemoglobins; D010545:Peroxides; C027767:elliptinium; D002570:Ceruloplasmin; D005978:Glutathione; D010100:Oxygen